- Lilly investing in future, staying out of biotech 'bubble'
- 4Q EARNINGS: Is 2015 Lilly's turning point?
- Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
- Amgen Q2 sales rise, but growth depends on Repatha and beyond
- PROFILE: Tomas Salmonson, chair of the EMA's CHMP, on European collaboration, being a teenage lifeguard, and Persian rugs
- Profile: Eurofarma's Martha Novelli Penna On Innovation And Acting